Supplementary Table 1. Phase III and LTE studies included in this analysis (1)

Study name	ClinicalTrials.gov identifier	Patients receiving tofacitinib, n	Patient population	Tofacitinib dose	Control group	Study duration
Phase III						
ORAL Step, A3921032 (2)	NCT00960440	267	Patients with moderate to severe RA with inadequate response to TNFi	5 or 10 mg BID with background MTX	Placebo	6 months
ORAL Solo, A3921045 (3)	NCT00814307	610	Patients with active RA with inadequate response to ≥1 DMARD	5 or 10 mg BID monotherapy	Placebo (advanced to tofacitinib at month 3)	6 months
ORAL Sync, A3921046 (4)	NCT00856544	792	Patients with active RA with inadequate	5 or 10 mg BID with background csDMARD	Placebo (non-responders advanced to	12 months

			response to ≥1 DMARD		tofacitinib at month 3; all remaining placebo patients advanced to placebo at month 6)	
ORAL Start, A3921069 (5)	NCT01039688	770	MTX-naïve patients with active RA	5 or 10 mg BID monotherapy	MTX	24 months
ORAL Scan, A3921044 (6)	NCT00847613	797	Patients with active RA with inadequate response to MTX	5 or 10 mg BID with background MTX	Placebo (non-responders advanced to tofacitinib at month 3; all remaining placebo patients advanced to placebo at month 6)	24 months

ORAL Standard, A3921064 (7)	NCT00853385	513	Patients with active RA with incomplete response to MTX	5 or 10 mg BID with background MTX	Adalimumab 40 mg SC Q2W; placebo (non-responders advanced to tofacitinib at month 3; all remaining placebo patients advanced to placebo at month 6)	12 months
LTE						
ORAL Sequel, A3921024 (8, 9)	NCT00413699	2,308 (as of March 31, 2015)	Patients with active RA who participated in phase I, II, or III index studies	5 or 10 mg BID, concomitant DMARDs permitted	None	Ongoing

A3921041 (8-10)	NCT00661661	486	Japanese patients with active RA who participated in phase II studies A3921039 and A3921040 or phase III ORAL Scan	5 or 10 mg BID, concomitant DMARDs permitted	None	72 months

BID = twice daily; csDMARD = conventional synthetic DMARD; DMARD = disease-modifying antirheumatic drug; LTE = long-term extension; MTX = methotrexate; Q2W = every 2 weeks; RA = rheumatoid arthritis; SC = subcutaneous; TNFi = tumor necrosis factor inhibitor

References

1. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62.

2. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451–60.

3. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495–507.

4. Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159: 253–61.

5. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.

6. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559–70.

7. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.

8. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837–52.

9. Wollenhaupt J, Silverfield J, Lee EB, Terry K, Kwok K, Strengholt S, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: http://acrabstracts.org/abstract/tofacitinib-an-oral-janus-kinase-inhibitor-in-the-treatment-of-rheumatoid-arthritis-safety-and-efficacy-in-open-label-long-term-extension-studies-over-9-years/.

10. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016;18:34.